50 results
Page 2 of 3
PRER14A
krr9j6mcffz5b1yk
6 Oct 23
Preliminary revised proxy
9:40pm
8-K
EX-99.1
npjvubi
8 Sep 23
Material Modifications to Rights of Security Holders
5:05pm
8-K
EX-99.1
0wpno58hxti1eee k30
23 Jun 23
Entry into a Material Definitive Agreement
9:16am
PRE 14A
olp 5pgh45ctf
7 Apr 23
Preliminary proxy
4:02pm
8-K
EX-99.1
3t4bkl lsuywupcd
6 Sep 22
Regulation FD Disclosure
5:01pm
8-K
EX-99.2
cnde at6qwdlo1jxupo
4 Aug 22
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
6:01am
8-K
EX-99.2
87zw asrukrtgtb
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.3
vnu8q io5
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.2
6ur78hh
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
8-K
EX-99.1
8aolfz 1sadeq0wn6kr
5 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.2
uvfdt
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am